The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $4.04

Today's change0.00 0.00%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $4.04

Today's change0.00 0.00%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc closed at (U.S.)$4.04.

Over the last five days, shares are unchanged, but have gained 16.43% over the last year to date. This security has underperformed the S&P 500 by 21.71% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $4.04
  • High--
  • Low--
  • Bid / Ask(U.S.) $0.01 / (U.S.) $5.30
  • YTD % change+16.43%
  • Volume0
  • Average volume (10-day)1,991,502
  • Average volume (1-month)2,692,592
  • Average volume (3-month)2,591,928
  • 52-week range(U.S.) $3.26 to (U.S.) $6.28
  • Beta-2.22
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.26
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-140.40%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue129813
Total other revenue--------
Total revenue129813
Gross profit97611
Total cost of revenue4322
Total operating expense34393438
Selling / general / administrative8989
Research & development22282527
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income-22-30-26-25
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-24-32-117
Income after tax-24-32-117
Income tax, total0----0
Net income-24-32-117
Total adjustments to net income--------
Net income before extra. items-24-32-117
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-24-32-117
Inc. avail. to common incl. extra. items-24-32-117
Diluted net income-24-32-117
Dilution adjustment0------
Diluted weighted average shares236220220225
Diluted EPS excluding extraordinary itemsvalue per share-0.10-0.15-0.050.03
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.10-0.15-0.050.03